Equities

IFR US ECM Pricings

 |  Robert Sherwood

Spyre Therapeutics (US, biotech) ─ $275m ABB. 14.9m shares (Primary) at $18.50 versus $18.50 fixed price marketing and $18.92 last sale. JEFF, TDC, LEER, STFL. Upsized from $200m. Wall cross.

 

Topics
Americas North America United States Equity Capital Structured Equity Marketed Follow-Ons US Dollar Initial Public Offerings (IPO) ABBs and Block Trades
Issuers
Spyre Therapeutics Inc (SYRE.O)